Pulmonary langerhans cell histiocytosis

Summary

Pulmonary langerhans cell histiocytosis (MONDO:0975907) is a disease and 3 clinical trials. A subtype of Langerhans cell histiocytosis — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 3

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	pulmonary langerhans cell histiocytosis
Mondo ID	MONDO:0975907
Orphanet	687733
UMLS	C1455705
MedGen	264101
GARD	0027418
Is cancer (heuristic)	no

Disease family

This is a subtype of Langerhans cell histiocytosis. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › immune system disorder › lymphoid system disorder › lymphatic system disorder › histiocytosis › Langerhans cell histiocytosis › pulmonary langerhans cell histiocytosis

Related subtypes (7): Langerhans cell histiocytosis specific to childhood, Langerhans cell histiocytosis specific to adulthood, eosinophilic granuloma, hand-Schuller-Christian disease, unifocal langerhans cell histiocytosis, single-system multifocal langerhans cell histiocytosis, multisystem langerhans cell histiocytosis

Subtypes (1): adult pulmonary Langerhans cell histiocytosis

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 3.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	3

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01651507	Not specified	COMPLETED	Evaluation of Outcome of Adult Pulmonary Langerhans Cell Histiocytosis Based on Lung HRCT and Lung Function
NCT03052101	Not specified	COMPLETED	Assessment of Safety of Air Travel in Patients With Pulmonary Langerhans Cell Histiocytosis
NCT05114304	Not specified	UNKNOWN	Prevalence of Mood and Anxiety Disorders in Adult Patients With Pulmonary Langerhans Cell Histiocytosis